<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="f2fc3b85-ad95-4e79-b523-5dab8ff96c96"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use TIOPRONIN TABLETS safely and effectively. See full prescribing information for TIOPRONIN TABLETS.<br/>
         <br/>
      </content>
      <content styleCode="bold"> </content>
      <content styleCode="bold">TIOPRONIN tablets, for oral use<br/>
      </content>
      <content styleCode="bold">Initial U.S. Approval: 1988</content>
   </title>
   <effectiveTime value="20250414"/>
   <setId root="8dee6eff-0ec1-4fe7-8d27-18cdc6cf54b9"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="001627975" root="1.3.6.1.4.1.519.1"/>
            <name>Teva Pharmaceuticals USA, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3fc8bad0-20f9-4bcd-ab0d-9e06739870ce"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250414"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0093-7909" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Tiopronin</name>
                        <formCode code="C42992" displayName="TABLET, SUGAR COATED" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Tiopronin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C5W04GO61S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TIOPRONIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="C5W04GO61S" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TIOPRONIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3UP11403C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSE (7 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="UKE75GEA7F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (90000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7773C1ROEU" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 130000 MW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G7515SW10N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL MONOCAPRYLOCAPRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="230OU9XXE4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL MONOSTEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C9H2L21V7U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEDIUM-CHAIN TRIGLYCERIDES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3350</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0093-7909-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20210517"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA214326" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210517"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>White to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">W</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_e54eaf0c-aa13-4d44-911f-9bfe9f1fdc5c">
               <id root="b77e551e-1bb1-49a9-bdd3-a9bacc4722cd"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Tiopronin tablets are indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Additional pediatric use information is approved for Mission Pharmacal Company’s Thiola (tiopronin) tablets. However, due to Mission Pharmacal Company’s marketing exclusivity rights, this drug product is not labeled with that information.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250414"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tiopronin is a reducing and complexing thiol indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone. (<linkHtml href="#LINK_e54eaf0c-aa13-4d44-911f-9bfe9f1fdc5c">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_94109e27-eafa-4c0d-8722-491533474dd5">
               <id root="2eee6a78-403e-45de-bcd0-6e07615eefa4"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20250414"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended initial dosage in adult patients is 800 mg/day. In clinical studies, the average dosage was about 1,000 mg/day. (<linkHtml href="#LINK_26395241-bc58-48bf-83c6-e49acb2829e2">2.1</linkHtml>)</item>
                           <item>The recommended initial dosage in pediatric patients 9 years of age and older is 15 mg/kg/day. Avoid dosages greater than 50 mg/kg per day in pediatric patients. (<linkHtml href="#LINK_26395241-bc58-48bf-83c6-e49acb2829e2">2.1</linkHtml>, <linkHtml href="#LINK_268ee262-a6c1-4985-818d-32d1ddd8378f">5.1</linkHtml>, <linkHtml href="#LINK_9651c9d4-d4e6-472f-b8f6-d4f2dbba61c7">8.4</linkHtml>)</item>
                           <item>Administer tiopronin tablets in 3 divided doses at the same times each day at least one hour before or 2 hours after meals. (<linkHtml href="#LINK_26395241-bc58-48bf-83c6-e49acb2829e2">2.1</linkHtml>)</item>
                           <item>Measure urinary cystine 1 month after initiation of tiopronin tablets and every 3 months thereafter. (<linkHtml href="#LINK_26395241-bc58-48bf-83c6-e49acb2829e2">2.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_26395241-bc58-48bf-83c6-e49acb2829e2">
                     <id root="e786c2e2-a261-423d-9d25-3241ee67b7c8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adults</content>: The recommended initial dosage in adult patients is 800 mg/day. In clinical studies, the average dosage was about 1,000 mg/day.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatrics</content>: The recommended initial dosage in pediatric patients 9 years of age and older is 15 mg/kg/day. Avoid dosages greater than 50 mg/kg per day in pediatric patients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_268ee262-a6c1-4985-818d-32d1ddd8378f">5.1</linkHtml>), Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_9651c9d4-d4e6-472f-b8f6-d4f2dbba61c7">8.4</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Additional pediatric use information is approved for Mission Pharmacal Company’s Thiola (tiopronin) tablets. However, due to Mission Pharmacal Company’s marketing exclusivity rights, this drug product is not labeled with that information.</content>
                           <br/>
                        </paragraph>
                        <paragraph>Administer tiopronin tablets in 3 divided doses at the same times each day at least one hour before or 2 hours after meals.</paragraph>
                        <paragraph>Consider starting tiopronin tablets at a lower dosage in patients with history of severe toxicity to d-penicillamine.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ae4101ac-98b0-4dcd-8bd0-a0667ea8004d">
                     <id root="d7ec00b1-fb99-4fd1-abf9-3d271c578097"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Monitoring</title>
                     <text>
                        <paragraph>Measure urinary cystine 1 month after starting tiopronin tablets and every 3 months thereafter. Adjust tiopronin tablets dosage to maintain urinary cystine concentration less than 250 mg/L.</paragraph>
                        <paragraph>Assess for proteinuria before treatment and every 3 to 6 months during treatment <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_268ee262-a6c1-4985-818d-32d1ddd8378f">5.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Discontinue tiopronin tablets in patients who develop proteinuria, and monitor urinary protein and renal function. Consider restarting tiopronin tablets treatment at a lower dosage after resolution of proteinuria.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_8d304253-ddc5-4f73-9e6b-a310c65ae429">
               <id root="8b59bb73-bbd1-4209-b512-830876d40110"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Tablets for oral use:</paragraph>
                  <paragraph>100 mg tablets: White to off-white round shaped, sugar coated tablets, imprinted with <content styleCode="underline">W</content> on one side in black ink.</paragraph>
               </text>
               <effectiveTime value="20250414"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 100 mg (<linkHtml href="#LINK_8d304253-ddc5-4f73-9e6b-a310c65ae429">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_28e66f97-39e2-493a-bde5-03b3b8b399ba">
               <id root="d1048b69-6193-48d7-8758-463fa64cb70c"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Tiopronin is contraindicated in patients with hypersensitivity to tiopronin or any other components of tiopronin tablets <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_5d500b29-3a30-4cd7-a6fc-e4c8273ef828">5.2</linkHtml>)]</content>.</paragraph>
               </text>
               <effectiveTime value="20250414"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Hypersensitivity to tiopronin or any component of tiopronin tablets. (<linkHtml href="#LINK_28e66f97-39e2-493a-bde5-03b3b8b399ba">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_5da03a55-6cf3-43ed-aa05-5b795a2fcf91">
               <id root="b222169b-a76d-41e1-8a3e-b5dc7ca2e903"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20250414"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Proteinuria, including nephrotic syndrome, and membranous nephropathy, has been reported with tiopronin use. Pediatric patients receiving greater than 50 mg/kg of tiopronin per day may be at increased risk for proteinuria. (<linkHtml href="#LINK_26395241-bc58-48bf-83c6-e49acb2829e2">2.1</linkHtml>, <linkHtml href="#LINK_268ee262-a6c1-4985-818d-32d1ddd8378f">5.1</linkHtml>, <linkHtml href="#LINK_9651c9d4-d4e6-472f-b8f6-d4f2dbba61c7">8.4</linkHtml>)</item>
                           <item>Hypersensitivity Reactions have been reported during tiopronin treatment. (<linkHtml href="#LINK_28e66f97-39e2-493a-bde5-03b3b8b399ba">4</linkHtml>, <linkHtml href="#LINK_5d500b29-3a30-4cd7-a6fc-e4c8273ef828">5.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_268ee262-a6c1-4985-818d-32d1ddd8378f">
                     <id root="ea15917f-6b6b-4d94-9990-38c6e47d6ccf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Proteinuria</title>
                     <text>
                        <paragraph>Proteinuria, including nephrotic syndrome, and membranous nephropathy, have been reported with tiopronin use. Pediatric patients receiving greater than 50 mg/kg of tiopronin per day may be at increased risk for proteinuria <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_ae4101ac-98b0-4dcd-8bd0-a0667ea8004d">2.2</linkHtml>), Adverse Reactions (<linkHtml href="#www.splportal.comLINK_7ecb81ca-044d-4435-b40f-c5f12fd1724b">6.1</linkHtml>, <linkHtml href="#www.splportal.comLINK_ba41d75b-8170-4b48-bffc-ba392724f443">6.2</linkHtml>), Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_9651c9d4-d4e6-472f-b8f6-d4f2dbba61c7">8.4</linkHtml>)]</content>. Monitor patients for the development of proteinuria and discontinue therapy in patients who develop proteinuria <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_ae4101ac-98b0-4dcd-8bd0-a0667ea8004d">2.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5d500b29-3a30-4cd7-a6fc-e4c8273ef828">
                     <id root="ed9f412d-a5b2-4208-814c-51d573236875"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Hypersensitivity reactions (drug fever, rash, fever, arthralgia and lymphadenopathy) have been reported <content styleCode="italics">[see Contraindications (<linkHtml href="#www.splportal.comLINK_28e66f97-39e2-493a-bde5-03b3b8b399ba">4</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_0178f8ac-a85d-403a-aa95-816dd29368aa">
               <id root="f61c7bc9-070e-4d2b-bb89-a24b71917d8d"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in greater detail in other sections of the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Proteinuria <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_268ee262-a6c1-4985-818d-32d1ddd8378f">5.1</linkHtml>)]</content>
                     </item>
                     <item>Hypersensitivity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_5d500b29-3a30-4cd7-a6fc-e4c8273ef828">5.2</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250414"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (≥10%) are nausea, diarrhea or soft stools, oral ulcers, rash, fatigue, fever, arthralgia, proteinuria, and emesis. (<linkHtml href="#LINK_0178f8ac-a85d-403a-aa95-816dd29368aa">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_7ecb81ca-044d-4435-b40f-c5f12fd1724b">
                     <id root="3f22ef51-0122-4680-820a-547ce65a536f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of the drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>Adverse reactions occurring at an incidence of ≥5% in an uncontrolled trial in 66 patients with cystinuria age 9 to 68 years are shown in the table below. Patients in group 1 had previously been treated with d-penicillamine; those in group 2 had not. Of those patients who had stopped taking d-penicillamine due to toxicity (34 out of 49 patients in group 1), 22 were able to continue treatment with tiopronin. In those without prior history of d-penicillamine treatment, 6% developed reactions of sufficient severity to require tiopronin withdrawal.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1</content> presents adverse reactions ≥5% in either treatment group occurring in this trial.</paragraph>
                        <table width="800px" cellspacing="0" cellpadding="5">
                           <caption>Table 1: Adverse Reactions Occurring in One or More Patients</caption>
                           <col width="239.4pt"/>
                           <col width="239.4pt"/>
                           <col width="121px"/>
                           <col width="121px"/>
                           <tbody>
                              <tr>
                                 <td valign="bottom" styleCode=" Botrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">System Organ Class</content>
                                    </paragraph>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Botrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">Group 1</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Previously treated</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">with</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">d-penicillamine</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=49)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Botrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">Group 2</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Naïve to</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">d-penicillamine</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=17)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom">
                                    <paragraph>Blood and Lymphatic System Disorders</paragraph>
                                 </td>
                                 <td valign="bottom">
                                    <paragraph>anemia</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>1 (2%)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>1 (6%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom">
                                    <paragraph>Gastrointestinal Disorders</paragraph>
                                 </td>
                                 <td valign="bottom">
                                    <paragraph>nausea</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>12 (25%)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>2 (12%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom"/>
                                 <td valign="bottom">
                                    <paragraph>emesis</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>5 (10%)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>–</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom"/>
                                 <td valign="bottom">
                                    <paragraph>diarrhea/soft stools</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>9 (18%)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>1 (6%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom"/>
                                 <td valign="bottom">
                                    <paragraph>abdominal pain</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>–</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>1 (6%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom"/>
                                 <td valign="bottom">
                                    <paragraph>oral ulcers</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>6 (12%)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>3 (18%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom">
                                    <paragraph>General Disorders and Administration Site Conditions</paragraph>
                                 </td>
                                 <td valign="bottom">
                                    <paragraph>fever</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>4 (8%)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>–</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom"/>
                                 <td valign="bottom">
                                    <paragraph>weakness</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>2 (4%)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>2 (12%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom"/>
                                 <td valign="bottom">
                                    <paragraph>fatigue</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>7 (14%)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>–</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom"/>
                                 <td valign="bottom">
                                    <paragraph>peripheral (edema)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>3 (6%)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>1 (6%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom"/>
                                 <td valign="bottom">
                                    <paragraph>chest pain</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>–</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>1 (6%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom">
                                    <paragraph>Metabolism and Nutrition Disorders</paragraph>
                                 </td>
                                 <td valign="bottom">
                                    <paragraph>anorexia</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>4 (8%)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>–</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom">
                                    <paragraph>Musculoskeletal and Connective Tissue Disorders</paragraph>
                                 </td>
                                 <td valign="bottom">
                                    <paragraph>arthralgia</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>–</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>2 (12%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom">
                                    <paragraph>Renal and Urinary Disorders</paragraph>
                                 </td>
                                 <td valign="bottom">
                                    <paragraph>proteinuria</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>5 (10%)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>1 (6%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom"/>
                                 <td valign="bottom">
                                    <paragraph>impotence</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>–</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>1 (6%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom">
                                    <paragraph>Respiratory, Thoracic and Mediastinal Disorders</paragraph>
                                 </td>
                                 <td valign="bottom">
                                    <paragraph>cough</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>–</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>1 (6%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom">
                                    <paragraph>Skin and Subcutaneous Tissue Disorders</paragraph>
                                 </td>
                                 <td valign="bottom">
                                    <paragraph>rash</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>7 (14%)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>2 (12%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom"/>
                                 <td valign="bottom">
                                    <paragraph>ecchymosis</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>3 (6%)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>–</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom"/>
                                 <td valign="bottom">
                                    <paragraph>pruritus</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>2 (4%)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>1 (6%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom"/>
                                 <td valign="bottom">
                                    <paragraph>urticaria</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>4 (8%)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>–</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Botrule"/>
                                 <td valign="bottom" styleCode=" Botrule">
                                    <paragraph>skin wrinkling</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule">
                                    <paragraph>3 (6%)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule">
                                    <paragraph>1 (6%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Taste Disturbance</content>
                           <br/>
                        </paragraph>
                        <paragraph>A reduction in taste perception may develop. It is believed to be the result of chelation of trace metals by tiopronin. Hypogeusia is often self-limited.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ba41d75b-8170-4b48-bffc-ba392724f443">
                     <id root="b91cb4b0-9866-4e08-bbb6-5662b2615e7d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>Adverse reactions have been reported from the literature, as well as during postapproval use of tiopronin. Because the postapproval reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to tiopronin exposure.</paragraph>
                        <paragraph>Adverse reactions reported during the postmarketing use of tiopronin are listed by body system in <content styleCode="bold">Table 2</content>.</paragraph>
                        <table width="800px" cellspacing="0" cellpadding="5">
                           <caption>Table 2: Adverse Reactions Reported for Tiopronin Pharmacovigilance by System Organ Class and Preferred Term</caption>
                           <col width="275.4pt"/>
                           <col width="275.4pt"/>
                           <tbody>
                              <tr>
                                 <td valign="bottom" styleCode=" Botrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">System Organ Class</content>
                                    </paragraph>
                                 </td>
                                 <td valign="bottom" styleCode=" Botrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">Preferred Term</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Cardiac Disorders</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>congestive heart failure</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Ear and Labyrinth Disorder</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>vertigo</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Gastrointestinal Disorders</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>abdominal discomfort; abdominal distension; abdominal pain; chapped lips; diarrhea; dry mouth; dyspepsia; eructation; flatulence; gastrointestinal disorder; gastroesophageal reflux disease; nausea; vomiting; jaundice; liver transaminitis</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>General Disorders and Administration Site Conditions</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>asthenia; chest pain; fatigue; malaise; pain; peripheral swelling; pyrexia; swelling</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Investigations</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>glomerular filtration rate decreased; weight increased</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Metabolism and Nutrition Disorders</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>decreased appetite; dehydration; hypophagia</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Musculoskeletal and Connective Tissue Disorders</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>arthralgia; back pain; flank pain; joint swelling; limb discomfort; musculoskeletal discomfort; myalgia; neck pain; pain in extremity</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Nervous System Disorders</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>ageusia; burning sensation; dizziness; dysgeusia; headache; hypoesthesia</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Renal and Urinary Disorders</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>nephrotic syndrome; proteinuria; renal failure</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule">
                                    <paragraph>Skin and Subcutaneous Tissue Disorders</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule">
                                    <paragraph>dry skin; hyperhidrosis; pemphigus foliaceus; pruritus; rash; rash pruritic; skin irritation; skin texture abnormal; skin wrinkling; urticaria</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_28761c98-8bbc-4b25-802b-2f81d5f044d1">
               <id root="d1614e52-22de-448f-9ac5-e7a6ec9a8129"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20250414"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Lactation: Breastfeeding is not recommended. (<linkHtml href="#LINK_84212ca4-c025-43e7-bf9e-309ced52e4eb">8.2</linkHtml>)</item>
                           <item>Geriatric: Choose dose carefully and monitor renal function in the elderly. (<linkHtml href="#LINK_93b6f5d9-dad4-4309-9138-f44bb2e56ec0">8.5</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Additional pediatric use information is approved for Mission Pharmacal Company’s Thiola (tiopronin) tablets. However, due to Mission Pharmacal Company’s marketing exclusivity rights, this drug product is not labeled with that information.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_9db656bc-75ac-43c9-a8ea-adf611a00791">
                     <id root="846b5dca-b99b-4796-a322-842a6b384c99"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Available published case report data with tiopronin have not identified a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Renal stones in pregnancy may result in adverse pregnancy outcomes <content styleCode="italics">(see Clinical Considerations)</content>. In animal reproduction studies, there were no adverse developmental outcomes with oral administration of tiopronin to pregnant mice and rats during organogenesis at doses up to 2 times a 2 grams/day human dose (based on mg/m<sup>2</sup>). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-associated maternal and/or embryo/fetal risk</content>
                        </paragraph>
                        <paragraph>Renal stones in pregnancy may increase the risk of adverse pregnancy outcomes, such as preterm birth and low birth weight.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>No findings of fetal malformations could be attributed to the drug in reproduction studies in mice and rats at doses up to 2 times the highest recommended human dose of 2 grams/day (based on mg/m<sup>2</sup>).</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_84212ca4-c025-43e7-bf9e-309ced52e4eb">
                     <id root="255a4e86-34e0-4bdf-b237-0603b75572af"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of tiopronin in either human or animal milk or on the effects of the breastfed child. A published study suggests that tiopronin may suppress milk production. Because of the potential for serious adverse reactions, including nephrotic syndrome, advise patients that breastfeeding is not recommended during treatment with tiopronin.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9651c9d4-d4e6-472f-b8f6-d4f2dbba61c7">
                     <id root="248a4afe-b1ed-4d9e-b87a-3660363d1c86"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.4
Pediatric Use</title>
                     <text>
                        <paragraph>Tiopronin is indicated in pediatric patients 9 years of age and older with severe homozygous cystinuria, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation who are not responsive to these measures alone. This indication is based on safety and efficacy data from a trial in patients 9 years to 68 years of age and clinical experience. Proteinuria, including nephrotic syndrome, has been reported in pediatric patients. Pediatric patients receiving greater than 50 mg/kg tiopronin per day may be at greater risk <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_26395241-bc58-48bf-83c6-e49acb2829e2">2.1</linkHtml>, <linkHtml href="#www.splportal.comLINK_ae4101ac-98b0-4dcd-8bd0-a0667ea8004d">2.2</linkHtml>), Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_268ee262-a6c1-4985-818d-32d1ddd8378f">5.1</linkHtml>), Adverse Reactions (<linkHtml href="#www.splportal.comLINK_7ecb81ca-044d-4435-b40f-c5f12fd1724b">6.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Tiopronin tablets are not approved for use in pediatric patients weighing less than 20 kg or in pediatric patients unable to swallow tablets <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_26395241-bc58-48bf-83c6-e49acb2829e2">2.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Additional pediatric use information is approved for Mission Pharmacal Company’s Thiola (tiopronin) tablets. However, due to Mission Pharmacal Company’s marketing exclusivity rights, this drug product is not labeled with that information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_93b6f5d9-dad4-4309-9138-f44bb2e56ec0">
                     <id root="00f30459-d620-4ded-9030-0f855ec45ace"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_f6fd962b-f628-433f-86eb-f3aa2e3ed599">
               <id root="867f9194-2dfb-4b2c-bdb2-000a77453c6e"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>There is no information on overdosage with tiopronin.</paragraph>
               </text>
               <effectiveTime value="20250414"/>
            </section>
         </component>
         <component>
            <section ID="LINK_83adff9a-52a3-419f-8aed-73ac0c008fd4">
               <id root="dbb24826-064d-40d5-b288-525f83b0f095"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Tiopronin immediate-release tablets are a reducing and cystine-binding thiol drug (CBTD) for oral use. Tiopronin is N-(2-Mercaptopropionyl) glycine and has the following structure:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Tiopronin has the empirical formula C<sub>5</sub>H<sub>9</sub>NO<sub>3</sub>S and a molecular weight of 163.20. In this drug product tiopronin exists as a dl racemic mixture.</paragraph>
                  <paragraph>Tiopronin is a white to off-white crystalline powder, which is freely soluble in water.</paragraph>
                  <paragraph>Each tiopronin tablet contains 100 mg of tiopronin. The inactive ingredients in tiopronin tablets include colloidal silicon dioxide, corn starch, ethylcellulose, hydroxypropyl cellulose, lactose monohydrate, low substituted hydroxypropyl cellulose, magnesium stearate, silicified microcrystalline cellulose, and stearic acid. The tablets contain a coating that consists of glyceryl monocaprylocaprate, glyceryl monostearate, hypromellose 2910, medium chain triglycerides, polyvinyl alcohol-part hydrolyzed, polyethylene glycol 3350, sodium lauryl sulfate, sucrose, and talc. In addition, the imprinting ink contains ammonium hydroxide, black iron oxide, propylene glycol, and shellac.</paragraph>
               </text>
               <effectiveTime value="20250414"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_b47070b3-fd47-42ba-a89c-8eb73f10beba">
               <id root="bdd12729-2f36-42b6-a54d-136f27b8825c"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text/>
               <effectiveTime value="20250414"/>
               <component>
                  <section ID="LINK_123199df-feb1-4f49-9546-3affcc838e51">
                     <id root="6b865981-6d4d-4e6d-9bb5-eb50dc45a285"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>The goal of therapy is to reduce urinary cystine concentration below its solubility limit. Tiopronin is an active reducing agent which undergoes thiol-disulfide exchange with cystine to form a mixed disulfide of tiopronin-cysteine. From this reaction, a water-soluble mixed disulfide is formed and the amount of sparingly soluble cystine is reduced.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_6bed2f55-21d1-4f92-8d05-cea5c21add2b">
                     <id root="5df1e547-91a9-402f-8289-5db03e2d3b0b"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The decrement in urinary cystine produced by tiopronin is generally proportional to the dose. A reduction in urinary cystine of 250 to 350 mg/day at tiopronin dosage of 1 g/day, and a decline of approximately 500 mg/day at a dosage of 2 g/day, might be expected. Tiopronin has a rapid onset and offset of action, showing a fall in cystine excretion on the first day of administration and a rise on the first day of drug withdrawal.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">
                     <id root="7c435333-8165-45c6-8c17-3b0e403d5f71"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Tiopronin </content>
                           <content styleCode="italics">Tablets</content>
                        </paragraph>
                        <paragraph>When tiopronin single doses were given to fasted healthy subjects (n=39), the median time to peak plasma level (T<sub>max</sub>) was 1 (range: 0.5 to 2.1) hours.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>When tiopronin is given orally, up to 48% of dose appears in urine during the first 4 hours and up to 78% by 72 hours.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_24ca90b2-6335-4021-b922-370a464aff0f">
               <id root="bedf7de4-4268-4bd7-89b3-f76d27ed9c10"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250414"/>
               <component>
                  <section ID="LINK_7dfb4b13-fed6-4f25-bc49-5068301c5035">
                     <id root="8b101b2c-0f0e-4b00-9989-93c66dccdd21"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Long-term carcinogenicity studies in animals have not been performed.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Tiopronin was not genotoxic in the chromosomal aberration, sister chromatid exchange, and <content styleCode="italics">in vivo</content> micronucleus assays.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>High doses of tiopronin in experimental animals have been shown to interfere with maintenance of pregnancy and viability of the fetus. In 2 published male fertility studies in rats, tiopronin at 20 mg/kg/day intramuscular (IM) for 60 days induced reductions in testis, epididymis, vas deferens, and accessory sex glands weights and in the count and motility of cauda epididymal sperm.</paragraph>
                     </text>
                     <effectiveTime value="20250414"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_387b587b-343a-4327-b60a-f786616c708b">
               <id root="e4abdece-ff85-4604-9c65-4cd82deb64e4"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>100 mg: Each white to off-white round shaped, sugar coated tablet, imprinted with <content styleCode="underline">W</content> on one side in black ink contains 100 mg of tiopronin. Tablets are available in bottles of 100 (NDC 0093-7909-01).</paragraph>
                  <paragraph>Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20250414"/>
            </section>
         </component>
         <component>
            <section ID="LINK_fcf3a7bf-ecc7-4005-8ed7-c038b8ade9ef">
               <id root="08d8e933-919d-4ac2-ba0c-f345618d1374"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise women that breastfeeding is not recommended during treatment with tiopronin tablets <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_84212ca4-c025-43e7-bf9e-309ced52e4eb">8.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>Manufactured In India By:<br/>
                     <content styleCode="bold">Watson Pharma Private Limited<br/>
                     </content>Verna, Salcette Goa 403 722 India</paragraph>
                  <paragraph>Manufactured For:<br/>
                     <content styleCode="bold">Teva Pharmaceuticals <br/>
                     </content>Parsippany, NJ 07054</paragraph>
                  <paragraph>Rev. A 9/2024</paragraph>
               </text>
               <effectiveTime value="20250414"/>
            </section>
         </component>
         <component>
            <section ID="LINK_d2c8b556-9f79-4f11-bb8f-439cf3f8de83">
               <id root="83f9178d-f15f-4e9b-9c1d-0cd628426ddc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 0093-7909-01</paragraph>
                  <paragraph>Tiopronin Tablets</paragraph>
                  <paragraph>100 mg </paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>100 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20250414"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>100mg100tabs</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>